



29 January 2019

ASX ANNOUNCEMENT

IMPEDIMED LIMITED ACN 089 705 144

PREVENT Trial Accepted for Publication and Presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), today announced that the prespecified, interim detailed results of the PREVENT trial will be presented during the scientific session of the 2019 Annual Meeting of the American Society of Breast Surgeons (ASBrS) in Dallas, Texas, 30 April to 5 May.

ASBrS is the primary leadership organisation for general surgeons who treat patients with breast disease and is committed to continually improving the practice of breast surgery by serving as an advocate for surgeons who seek excellence in the care of breast patients. The results of the PREVENT trial are subject to the embargo policy of the ASBrS 20th Annual Meeting. All scientific abstracts accepted for oral or poster presentation during the Society's 20th Annual Meeting, press releases, and the Society's Official Proceedings are embargoed until 12.30 p.m. Eastern time, 2 May 2019.

The full PREVENT manuscript has been accepted for publication by the Annals of Surgical Oncology and will be released immediately following the presentation by the PREVENT trial principal investigator. Annals of Surgical Oncology is one of the leading journals in Oncology and Surgery and features original articles on the latest advances in oncology for surgeons from all specialties. The full manuscript will provide detailed analysis of the top line results previously announced to the market.

Richard Carreon, Managing Director and CEO of ImpediMed said: "We're pleased and honoured that the groundbreaking trial results were selected by the ASBrS for podium

presentation during the scientific session at the upcoming annual meeting. PREVENT is a landmark study, the most rigorously conducted trial for evaluating the impact of BIS on detecting, monitoring and treating cancer-related lymphoedema. The opportunity to highlight the results of the PREVENT trial at the prestigious ASBrS meeting exemplifies our commitment to improve the quality of care for millions of cancer survivors suffering from lymphoedema worldwide. We look forward to partnering with our medical advisors to enhance awareness and improve reimbursement for the detection, monitoring and treatment of this devastating condition.”

We will be discussing this information and our private payor reimbursement timeline in the upcoming investor conference call on Wednesday, 30 January 2019.

Richard Carreon
Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan

T: +61 3 9866 4722

E: kwilliamson@we-buchan.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.

About the PREVENT Trial

In the PREVENT trial, *A Randomized Trial Evaluating Bioimpedance Spectroscopy versus Tape Measure in the Prevention of Lymphedema Following Locoregional Treatment for Breast Cancer (PREVENT)*, 1,100 breast cancer patients at risk for lymphoedema are randomised for regular monitoring either with BIS or with Tape Measure for up to 3 years post-surgery. If they meet the criteria for intervention, they are prescribed compression garments for 28 days. As of January 2018, 109 participants have triggered intervention: 68 in the tape measure group, which had 10 patients with lymphoedema progression, and 41 in the BIS group, with only 2 patients with lymphoedema progression.

About BIS

BIS is the only non-invasive, low-cost, field technology available that has the potential to accurately measure tissue composition and fluid status in a non-invasive manner using 256 different frequencies. BIS provides a more direct, individualised measurement of extracellular and intracellular fluid (ECF and ICF) than other bioimpedance approaches.

About the ASBrS Embargo Policy

All scientific abstracts accepted for oral or poster presentation during the Society's 20th Annual Meeting, press releases, and the Society's Official Proceedings are embargoed until 12.30 p.m. Eastern time, 2 May 2019. The Society strictly enforces its embargo policy, which prohibits the distribution or publication of the contents of abstracts ahead of the embargo time. Embargoed press releases and official proceedings of the meeting will be distributed to registered credentialed press in advance of the meeting. Failure to abide by the Society's embargo policy will result in forfeiture of press credentials for this and future annual meetings.